Cargando…
Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)
Currently, treatment allocation of patients with Mantle Cell Lymphoma (MCL) is mainly based on age and medical fitness. The combined MCL International Prognostic Index (MIPI-c) allows to predict prognosis using clinical factors (MIPI) and the Ki-67 index. However, high p53 expression as surrogate fo...
Autores principales: | Scheubeck, Gabriel, Jiang, Linmiao, Hermine, Olivier, Kluin-Nelemans, Hanneke C., Schmidt, Christian, Unterhalt, Michael, Rosenwald, Andreas, Klapper, Wolfram, Evangelista, Andrea, Ladetto, Marco, Jerkeman, Mats, Ferrero, Simone, Dreyling, Martin, Hoster, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457193/ https://www.ncbi.nlm.nih.gov/pubmed/37495776 http://dx.doi.org/10.1038/s41375-023-01977-y |
Ejemplares similares
-
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022) -
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established high-risk factors
por: Gerdtsson, Anna Sandström, et al.
Publicado: (2022) -
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
por: Fischer, Luca, et al.
Publicado: (2023) -
Management of mantle cell lymphoma in the elderly patient
por: Doorduijn, Jeanette K, et al.
Publicado: (2013) -
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study
por: Nordström, Lena, et al.
Publicado: (2014)